BBC News

Inside the secretive and lucrative world of orchid breeding

Inside the secretive and lucrative world of orchid breeding

Title: Unveiling the High-Stakes, Hidden Industry of Orchid Breeding

Creating a new orchid variety is a marathon, not a sprint, often requiring ten years of rigorous effort before reaching the consumer. Although the financial incentives are substantial—the global orchid industry generates hundreds of millions of dollars annually—the rivalry to cultivate the next stunning bloom is fierce. Consequently, the race to innovate relies just as heavily on advanced laboratory science as it does on traditional greenhouse cultivation.

According to Floricultura, a prominent Dutch orchid breeding firm, centuries of human-directed selective breeding and propagation have left the genetic foundation of many commercial orchids in a state of disarray. This genetic complexity makes it nearly impossible to forecast the traits of potential new breeds. To counter this unpredictability, Floricultura and its rivals are utilizing genetic markers to accelerate selective breeding. These markers target specific attributes such as disease resistance, flower longevity, color, and shape. By applying genetic screening to seedlings at the earliest stages, breeders can eliminate unsuitable candidates immediately, rather than waiting three years for a plant to flower to assess its quality.

Wart van Zonneveld, Floricultura’s research and development manager, explains the efficiency of this method: "If a few thousand cross breeds [come] from the lab, we can screen them based on the marker and just select the ones that have the marker that you search for." He notes that this technique serves as an indicator for desired or undesired traits, allowing for precise selection early in the development cycle.

These so-called "novel breeding techniques" remain tightly guarded trade secrets. Because proprietary genetic markers and processes are the key to developing unique varieties, companies refuse to share them. "We keep it to ourselves because it's lots of investment," van Zonneveld states.

Paul Arens, an ornamental plant breeding researcher at the Netherlands' Wageningen University, adds nuance to the technological shift. While leading a government-backed initiative that facilitates information sharing among participating firms, he emphasizes that the core of the work remains traditional. "The foundation is still what we are doing for 100 years already. You take two plants, you look at their characteristics, and you make a cross," Arens says. However, he points out that modern breeders "have white lab coats" and employ genomics and marker research to assess plant health. "We cannot just pick out a piece of DNA and put it back that easily," he clarifies.

Genetics also play a critical role in safeguarding intellectual property. In Europe, new varieties are protected through breeders' rights, while the United States utilizes patents. "If a company makes a new orchid, then [it] would like the sole right to commercialize this orchid," Arens explains. Without such protections, competitors could simply purchase the plant, propagate it, and sell it independently. To qualify for these rights, a variety must be distinct, stable, and uniform. Although legal protections are granted based on physical descriptions rather than DNA analysis, genetic tools are indispensable for identifying which existing market products the new variety should be compared against to prove its distinctiveness.

"It's just like what we do in forensic science," Arens compares. "You run markers that are at different positions in the DNA and that gives you a pattern and then you have a chance to match it or not."

Floricultura operates exclusively in the B2B sector, selling neither to the general public nor to retail garden centers. Instead, their business model focuses on developing new varieties for large-scale cultivators. With over 180 varieties in their current catalog and several hundred more in development, the company faces relentless pressure to innovate. "You can't stop, because it takes so long to develop new varieties," says Stefan Kuiper, the company’s breeding manager. "You have to go on, [or] you will be behind the times."


Source: BBC News Generated at: 2026-05-14 23:03:16 UTC

Related Articles

Bloomberg

Trump to Keep Audit Immunity, Names Pulte Acting DNI, More

Trump maintains audit immunity and appoints Pulte as Acting DNI.

Bloomberg

Bloomberg Talks: Antonio Neri (Podcast)

Antonio Neri discusses his transition from Oracle to Apple, emphasizing the importance of design, user experience, and b...

Bloomberg

Bloomberg Tech: Anthropic Files For IPO (Podcast)

Bloomberg Tech reports that Anthropic has officially filed for an IPO, submitting the necessary paperwork to the SEC.

MSC Ship Is Struck by Two Projectiles in Iraqi Port
New York Times

MSC Ship Is Struck by Two Projectiles in Iraqi Port

An MSC ship was struck by two projectiles in an Iraqi port. Meanwhile, the U.S. has disabled five commercial vessels and...

Bloomberg

Bloomberg Intelligence: SpaceX Wants Bankers Fee Cut (Podcast)

Bloomberg Intelligence reports SpaceX is negotiating with bankers to reduce fees for its upcoming IPO. This move aims to...

Bloomberg

Inside Active: Baillie Gifford’s Coutts, Burns Look Beyond US

Baillie Gifford’s Coutts and Burns discuss Europe and Japan’s projected double-digit earnings growth, noting sector-spec...